Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBITDA: 2019-2025

Historic EBITDA for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to -$1.4 million.

  • Eton Pharmaceuticals' EBITDA fell 367.78% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 48.67%. This contributed to the annual value of -$2.6 million for FY2024, which is 117.87% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' EBITDA stood at -$1.4 million, which was up 7.59% from -$1.5 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' EBITDA peaked at $5.4 million during Q1 2021, and registered a low of -$5.8 million during Q3 2021.
  • For the 3-year period, Eton Pharmaceuticals' EBITDA averaged around -$645,182, with its median value being -$800,000 (2024).
  • Per our database at Business Quant, Eton Pharmaceuticals' EBITDA spiked by 389.78% in 2023 and then plummeted by 367.78% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' EBITDA (Quarterly) stood at $1.3 million in 2021, then fell by 19.18% to $1.1 million in 2022, then tumbled by 287.66% to -$2.0 million in 2023, then soared by 131.56% to $629,000 in 2024, then crashed by 367.78% to -$1.4 million in 2025.
  • Its EBITDA was -$1.4 million in Q3 2025, compared to -$1.5 million in Q2 2025 and -$470,000 in Q1 2025.